Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia - Remarkable activity with room for improvement

Ayalew Tefferi, Hagop Kantarjian

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)175-177
Number of pages3
JournalAmerican Journal of Hematology
Volume83
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Piperazines
Leukemia, Myeloid, Chronic Phase
Platelet-Derived Growth Factor Receptors
Pyrimidines
Protein Kinase Inhibitors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antineoplastic Agents
Mutation
Therapeutics
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology

Cite this

@article{2628dc5dcb684c3f850fb8572adec66b,
title = "Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia - Remarkable activity with room for improvement",
author = "Ayalew Tefferi and Hagop Kantarjian",
year = "2008",
month = "3",
doi = "10.1002/ajh.21136",
language = "English (US)",
volume = "83",
pages = "175--177",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia - Remarkable activity with room for improvement

AU - Tefferi, Ayalew

AU - Kantarjian, Hagop

PY - 2008/3

Y1 - 2008/3

UR - http://www.scopus.com/inward/record.url?scp=39749129060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749129060&partnerID=8YFLogxK

U2 - 10.1002/ajh.21136

DO - 10.1002/ajh.21136

M3 - Article

VL - 83

SP - 175

EP - 177

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -